Efficacy and pharmacodynamic effect of anti-CD73 and anti-PD-L1 monoclonal antibodies in combination with cytotoxic therapy: observations from mouse tumor models

Brajesh P. KaisthaGozde KarAndreas DannhornAmanda WatkinsGrace Opoku-AnsahKristina IlievaStefanie MullinsJudith AndertonElena GalvaniFabien GarconJean-Martin LapointeLee BrownJames HairTim SlidelNadia LuheshiKelli RyanElizabeth HardakerSimon DovediRakesh KumarRobert W. WilkinsonScott A. HammondJim Eylesa Oncology R & D,AstraZeneca,Cambridge,UKb Imaging Sciences,AstraZeneca,Cambridge,UKc Immunooncology,MorphoSys AG,Planegg,Germanyd Translational Science,F-Star,Cambridge,UKe Oncology Safety Pathology,AstraZeneca,Cambridge,UKf Oncology R & D,AstraZeneca,Gaithersburg,MD,USABrajesh P. Kaistha,obtained his PhD degree from Philipps University Marburg,Germany. He is currently Associate Principal Scientist in Oncology R&D at AstraZeneca. He led studies in this manuscript as in vivo Pharmacology lead.Gozde Kar received her Master's degree and PhD degree from Koc University,Turkey. She completed her postdoctoral research at EMBL-EBI and Sanger Institute,Cambridge. She is currently Associate Director in Oncology Data Science at AstraZeneca.Andreas Dannhorn received his PhD degree from Imperial College London after completing his undergraduate studies in Pharmacy at the Freie Universität Berlin. He is currently an Associate Director in Clinical Pharmacology and Safety Sciences at AstraZeneca.Amanda Watkins is currently Associate Principal Scientist in Oncology R&D at AstraZeneca.Grace Opoku-Ansah received her Bachelor's degree from Kingston University,London and currently is working as Scientist in Oncology R&D at AstraZeneca.Kristina Ilieva received her PhD from King's College London. She is currently working as Associate Director in Translational Immuno-Oncology & Autoimmunity in Morphosys,Germany.Stefanie Mullins received her PhD degree from Wayne State University and was a Postdoctoral Associate at Fox Chase Cancer Centre prior to becoming a Senior Scientist at AstraZeneca. She is currently a translational sciences lead at invoX pharmaceutical.Judith Anderton received her Master's Degree from the University of Liverpool and her Bachelor's degree from Manchester Metropolitan University. She is currently a Senior Scientist in Early Oncology R&D at AstraZeneca.Elena Galvani received her PhD from Parma University,Italy. She's currently a Senior Scientist in Oncology R&D at AstraZeneca.Fabien Garcon received his PhD degree from Aix-Marseille University. He's currently a Senior Scientist in Oncology R&D at AstraZeneca.Jean-Martin Lapointe received his Doctorate in veterinary Medicine from University of Montreal followed by a Residency and MS in Comparative Pathology from UC Davis. He is currently a Director in Oncology Safety Pathology at AstraZeneca.Lee Brown received his Bachelor's degree from University of Hertfordshire. He's currently a Senior Scientist in Imaging Sciences,AstraZeneca.James Hair earned his PhD in Immunology from Cambridge University UK. He is currently a Scientist in Oncology R&D at AstraZeneca.Tim Slidel received his PhD from University College London and Bachelor's degree from Leeds University. He is currently a Director in Oncology Data Science at AstraZeneca.Nadia Luheshi received her PhD from the University of Manchester and her Bachelor's degree from University of Cambridge. She is currently a global project leader in Oncology R&D at AstraZeneca.Kelli Ryan received her PhD degree from Emory University and bachelor's degree from Marquette University. She is currently a Director in Oncology R&D at AstraZeneca.Elizabeth Hardaker received her PhD from the National Heart and Lung Institute,Imperial College London and Master's degree from Bath University. At the time of working on this research Elizabeth was a Senior Director in Oncology R&D at AstraZeneca. Elizabeth is currently Vice President Biology at Epsilogen Ltd.Simon Dovedi read for his PhD at Newcastle University in Cancer Immunology and is an Executive Director and Head of IO Discovery in Oncology R&D at AstraZeneca.Rakesh Kumar,received his PhD degree from Banaras Hindu University in India. He is an Executive Director and Global Project Leader at AstraZeneca Oncology R&D.Robert W. Wilkinson received his PhD degree from the University of Birmingham and a Bachelor's degree from Aston University Birmingham UK. He is currently Vice President,Head of Oncology Research at Immunocore and has previously held scientific leadership positions at Cancer Research UK,MedImmune and AstraZeneca.Scott Hammond earned his PhD in Immunology from the Johns Hopkins University School of Medicine. He is a Senior Director in Oncology R&D at AstraZeneca.Jim Eyles received a BSc and then PhD from Aston University Birmingham UK. He is a Director in the Clinical Immuno-Oncology Discovery Group in Oncology R&D at AstraZeneca.

DOI: https://doi.org/10.1080/15384047.2023.2296048

2024-01-12

Cancer Biology & Therapy

Abstract:CD73 is a cell surface 5'nucleotidase (NT5E) and key node in the catabolic process generating immunosuppressive adenosine in cancer. Using a murine monoclonal antibody surrogate of Oleclumab, we investigated the effect of CD73 inhibition in concert with cytotoxic therapies (chemotherapies as well as fractionated radiotherapy) and PD-L1 blockade. Our results highlight improved survival in syngeneic tumor models of colorectal cancer (CT26 and MC38) and sarcoma (MCA205). This therapeutic outcome was in part driven by cytotoxic CD8 T-cells, as evidenced by the detrimental effect of CD8 depleting antibody treatment of MCA205 tumor bearing mice treated with anti-CD73, anti-PD-L1 and 5-Fluorouracil+Oxaliplatin (5FU+OHP). We hypothesize that the improved responses are tumor microenvironment (TME)-driven, as suggested by the lack of anti-CD73 enhanced cytopathic effects mediated by 5FU+OHP on cell lines in vitro . Pharmacodynamic analysis, using imaging mass cytometry and RNA-sequencing, revealed noteworthy changes in specific cell populations like cytotoxic T cells, B cells and NK cells in the CT26 TME. Transcriptomic analysis highlighted treatment-related modulation of gene profiles associated with an immune response, NK and T-cell activation, T cell receptor signaling and interferon (types 1 & 2) pathways. Inclusion of comparator groups representing the various components of the combination allowed deconvolution of contribution of the individual therapeutic elements; highlighting specific effects mediated by the anti-CD73 antibody with respect to immune-cell representation, chemotaxis and myeloid biology. These pre-clinical data reflect complementarity of adenosine blockade with cytotoxic therapy, and T-cell checkpoint inhibition, and provides new mechanistic insights in support of combination therapy.

oncology